Literature DB >> 31186840

The long-term horizon: Patients who will remain untreated in the era of triple therapy.

Andrew Aronsohn1, Donald Jensen1.   

Abstract

Entities:  

Year:  2012        PMID： 31186840      PMCID： PMC6490698          DOI： 10.1002/cld.5

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  23 in total

1.  Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.

Authors:  Naga Chalasani; Cosme Manzarbeitia; Peter Ferenci; Wolfgang Vogel; Robert J Fontana; Michael Voigt; Caroline Riely; Paul Martin; Lewis Teperman; James Jiao; Juan Carlos Lopez-Talavera
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

2.  Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

Authors:  Stefan Wirth; Heidrun Pieper-Boustani; Thomas Lang; Antje Ballauff; Ulrike Kullmer; Patrick Gerner; Philip Wintermeyer; Andreas Jenke
Journal:  Hepatology       Date:  2005-05       Impact factor: 17.425

3.  Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study.

Authors:  Naoshi Horikawa; Tomoko Yamazaki; Namiki Izumi; Masakatsu Uchihara
Journal:  Gen Hosp Psychiatry       Date:  2003 Jan-Feb       Impact factor: 3.238

4.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

5.  Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

Authors:  Angelo Iacobellis; Massimo Siciliano; Francesco Perri; Brigida E Annicchiarico; Gioacchino Leandro; Nazario Caruso; Laura Accadia; Giuseppe Bombardieri; Angelo Andriulli
Journal:  J Hepatol       Date:  2006-10-20       Impact factor: 25.083

6.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

Authors:  I Bica; B McGovern; R Dhar; D Stone; K McGowan; R Scheib; D R Snydman
Journal:  Clin Infect Dis       Date:  2001-01-23       Impact factor: 9.079

7.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Outcomes of acute rejection after interferon therapy in liver transplant recipients.

Authors:  Sammy Saab; Denise Kalmaz; Nupoor A Gajjar; Jonathan Hiatt; Francisco Durazo; Steven Han; Douglas G Farmer; R Mark Ghobrial; Hasan Yersiz; Leonard I Goldstein; Charles R Lassman; Ronald W Busuttil
Journal:  Liver Transpl       Date:  2004-07       Impact factor: 5.799

10.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.